B. Riley FBR Downgrades Acasti Pharma to Neutral, Announces $2 Price Target

B. Riley FBR downgrades Acasti Pharma (NASDAQ:ACST) from Buy to Neutral and announces $2 price target.

Benzinga · 01/13/2020 16:09

B. Riley FBR downgrades Acasti Pharma (NASDAQ:ACST) from Buy to Neutral and announces $2 price target.